Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Validates Multilyte's Basic Microarray IP Portfolio

NEW YORK (GenomeWeb News) — The US Patent and Trademark Office has issued an ex parte re-examination certificate to Multilyte for its basic microarray patent portfolio, validating the IP, Multilyte said this week.
 
The move, which strengthens Multilyte’s IP portfolio as it “endeavor[s] to license” them, was requested by the company and by Affymetrix ex parte.

 

“After careful examination stretching over two years, the USPTO concluded that all the claims are valid over more than 20 documents submitted by Affymetrix,” UK-based Multilyte said in a statement.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.